656
Participants
Start Date
July 31, 2009
Primary Completion Date
January 31, 2014
Study Completion Date
January 31, 2014
Everolimus
Everolimus was formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
Everolimus placebo
Placebo was formulated to be indistinguishable from the everolimus tablets, also formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
Best Supportive Care (BSC)
Best supportive care is defined as care in accordance with the local practice of an individual institution or center, specifically excluding anti-cancer treatments.
Novartis Investigative Site, San Isidro
Novartis Investigative Site, San Borja
Novartis Investigative Site, Canberra
Novartis Investigative Site, Leuven
Novartis Investigative Site, Footscray
Novartis Investigative Site, Heidelberg
Novartis Investigative Site, Box Hill
Novartis Investigative Site, Clayton
Novartis Investigative Site, Prahran
Novartis Investigative Site, Liège
Novartis Investigative Site, Herston
Novartis Investigative Site, North Adelaide
Novartis Investigative Site, Kurralta Park
Novartis Investigative Site, Charleroi
Novartis Investigative Site, Rio Negro
Novartis Investigative Site, Ghent
Novartis Investigative Site, Taipei
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Berlin
Novartis Investigative Site, Marseille
Novartis Investigative Site, Mexico City
Novartis Investigative Site, Rozzano
Novartis Investigative Site, Dijon
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Aviano
Novartis Investigative Site, Kuei-Shan Chiang
Novartis Investigative Site, Pessac
Novartis Investigative Site, Bielefeld
Novartis Investigative Site, Montpellier
Novartis Investigative Site, Rennes
Novartis Investigative Site, León
Novartis Investigative Site, Modena
Novartis Investigative Site, Petah Tikva
Novartis Investigative Site, Florence
Novartis Investigative Site, Reims
Novartis Investigative Site, Trier
Novartis Investigative Site, Mainz
University of Minnesota Cancer Center, Minneapolis
Novartis Investigative Site, Frankfurt
Novartis Investigative Site, Clermont-Ferrand
Novartis Investigative Site, Mannheim
Novartis Investigative Site, Lyon
Highlands Oncology Group DeptofHighlandsOncologyGrp(2), Fayetteville
Novartis Investigative Site, Paris
Novartis Investigative Site, Rehovot
The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD(2), Fort Worth
Novartis Investigative Site, Offenburg
Novartis Investigative Site, Frattamaggiore
Novartis Investigative Site, München
Novartis Investigative Site, Niaosong Township
Novartis Investigative Site, Avignon
Novartis Investigative Site, Poitiers
Novartis Investigative Site, Songkhla
Novartis Investigative Site, Clichy
Loma Linda Oncology Medical Group Loma Linda, Redlands
Novartis Investigative Site, Villejuif
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Moscow
Novartis Investigative Site, Harbin
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Nanjing
Novartis Investigative Site, Suzhou
Novartis Investigative Site, Hangzhou
Novartis Investigative Site, Guangzhou
Novartis Investigative Site, Guangzhou
Novartis Investigative Site, Chengdu
Novartis Investigative Site, Ramat Gan
Novartis Investigative Site, Jerusalem
Henry Ford Hospital Dept. of Henry Ford Hospital, Detroit
University of Texas Southwestern Medical Center DeptofSimmons Cancer Center(4), Dallas
University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology, Houston
University of Washington Cancer Care Seattle Cancer Alliance, Seattle
Novartis Investigative Site, Buenos Aires
Novartis Investigative Site, Córdoba
Novartis Investigative Site, North Vancouver
Novartis Investigative Site, Vancouver
Novartis Investigative Site, Toronto
Novartis Investigative Site, Toronto
Novartis Investigative Site, Montreal
Novartis Investigative Site, Sherbrooke
Novartis Investigative Site, Shijiazhuang
Novartis Investigative Site, Shenyang
Novartis Investigative Site, Hong Kong SAR
Novartis Investigative Site, Auckland
Novartis Investigative Site, Liouying Township
Novartis Investigative Site, Taipei
Novartis Investigative Site, Nice
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Kashiwa
Novartis Investigative Site, Matsuyama
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Sagamihara
Novartis Investigative Site, Sendai
Novartis Investigative Site, Sayama
Novartis Investigative Site, Takatsuki
Novartis Investigative Site, Kitaadachi-gun
Novartis Investigative Site, Utsunomiya
Novartis Investigative Site, Chuo-ku
Novartis Investigative Site, Koto
Novartis Investigative Site, Mitaka
Novartis Investigative Site, Amsterdam
Novartis Investigative Site, Jeonju
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Taegu
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Northwood
Novartis Investigative Site, Sutton
Novartis Investigative Site, East Yorkshire
Novartis Investigative Site, London
Novartis Investigative Site, London
Novartis Investigative Site, Manchester
Novartis Investigative Site, Wolverhampton
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY